We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

woensdag 1 februari 2017

Nature Reviews Neurology - Table of Contents alert Volume 13 Issue 2

If you are unable to see the message below, click here to view.

Nature Reviews Neurology

Focus on the neuroscience toolbox

Nature Neuroscience presents a special focus issue on the neuroscience toolbox highlighting recent technological advances, approaches and collaborative initiatives that are enabling new avenues of research. 

Access the Focus free online for six months

Produced with support from: 
The Kavli Foundation
February 2017 Volume 13 Number 2Advertisement

Nature Reviews Neurology cover
2015 2-year Impact Factor 18.418 Journal Metrics 2-year Median 13
In this issue
Research Highlights
Year in Review

Also this month
 Featured article:
The psychosis spectrum in Parkinson disease
Dominic H. ffytche, Byron Creese, Marios Politis, K. Ray Chaudhuri, Daniel Weintraub, Clive Ballard & Dag Aarsland


Animation: Alzheimer's disease

Nature Neuroscience presents this animation, which introduces the molecular, cellular and physiological mechanisms associated with Alzheimer's disease and highlights some of the most recent advances in our understanding of the onset and progression of this devastating neurological condition.

Watch the Animation free online >>

Recommend to library
An open access journal dedicated to highlighting the most important scientific advances in Parkinson's disease research, spanning the motor and non-motor disorders of Parkinson's disease.

Part of the Nature Partner Journals series, npj Parkinson's Disease is published in partnership with the Parkinson's Disease Foundation.

Open for submissions >>


Alzheimer disease: Soluble TREM2 in CSF sheds light on microglial activation in AD
Published online: 13 January 2017
p65 | doi:10.1038/nrneurol.2016.203


Parkinson disease: Could gut microbiota influence severity of Parkinson disease?
Published online: 16 December 2016
p66 | doi:10.1038/nrneurol.2016.195


Neuroimmunology: Could antibodies cause psychosis?
Published online: 23 December 2016
p66 | doi:10.1038/nrneurol.2016.198


Motor neuron disease: Nusinersen potentially effective in SMA
Published online: 23 December 2016
p66 | doi:10.1038/nrneurol.2016.199



Migraine: Migraine is associated with increased risk of perioperative ischaemic stroke | Stroke: Thrombolytic removal of intraventricular haemorrhage does not improve outcomes | Motor neuron disease: Sparing of oligodendrocytes in a mouse model of spinal muscular atrophy | Peripheral neuropathies: Atypical Charcot-Marie-Tooth disease linked to sphingosine 1-phosphate lyase deficiency

JOBS of the week
Research Fellow - Neurology
Mayo Clinic
Psychiatry - Research Faculty Position
The University of Alabama
More Science jobs from
15th European Neurology Congress
London, UK
More science events from

CNS Infections in 2016: 2016, the year of Zika virus
Diederik van de Beek & Matthijs C. Brouwer
Published online: 13 January 2017
p69 | doi:10.1038/nrneurol.2016.202
In 2016, the literature on neurological infections was, understandably, dominated by Zika virus. However, we should not overlook important publications on the treatment of cryptococcal and bacterial meningitis.
Full Text | PDF

Neuro-oncology in 2016: Advances in brain tumour classification and therapy
Matthias Preusser & Christine Marosi
Published online: 20 January 2017
p71 | doi:10.1038/nrneurol.2017.3
Brain tumours encompass a heterogeneous collection of neoplasms, traditionally classified by histopathological criteria. In 2016, the WHO published an updated classification that, for the first time, defines brain tumour types according to integrated histological and molecular parameters. Furthermore, clinical trial results were reported that inform therapeutic decision-making in diffuse gliomas.
Full Text | PDF

Multiple sclerosis in 2016: Immune-directed therapies in MS — efficacy and limitations
Bernhard Hemmer & Mark Mühlau
Published online: 20 January 2017
p72 | doi:10.1038/nrneurol.2017.2
In 2016, new highly active treatment options for relapsing-remitting multiple sclerosis (MS) emerged. At the same time, large clinical trials in progressive MS highlighted the limitations of immune-directed therapies, and called for new strategies to treat disease progression in MS.
Full Text | PDF

Alzheimer disease in 2016: Putting AD treatments and biomarkers to the test
Eric M. Reiman
Published online: 13 January 2017
p74 | doi:10.1038/nrneurol.2017.1
Investigational treatments to impede the progression of Alzheimer disease (AD) are being evaluated in clinical trials, and biomarkers to detect and track the disease are being developed and deployed. Recent findings underscore the importance of ongoing clinical trials and biomarker developments in the understanding, treatment and prevention of AD.
Full Text | PDF

Movement disorders in 2016: Progress in Parkinson disease and other movement disorders
Joseph Jankovic
Published online: 13 January 2017
p76 | doi:10.1038/nrneurol.2016.204
In the field of movement disorders, areas that have seen important advances in 2016 include the pathogenesis of Parkinson disease involving extra-CNS α-synuclein pathology, treatment of hyperkinetic disorders with novel dopamine-depleting drugs, and MRI-guided ultrasound surgery for the treatment of essential tremor.
Full Text | PDF

Stroke in 2016: Stroke is treatable, but prevention is the key
Ale Algra & Marieke J. H. Wermer
Published online: 20 January 2017
p78 | doi:10.1038/nrneurol.2017.4
The past 2 years have seen major breakthroughs in endovascular treatment for acute ischaemic stroke. As highlighted in 2016, we now need to refine the logistics for delivery of this treatment, including patient selection. We should not forget, however, that it is better to prevent strokes in the first place.
Full Text | PDF


The psychosis spectrum in Parkinson disease
Dominic H. ffytche et al.
Published online: 20 January 2017
p81 | doi:10.1038/nrneurol.2016.200
The publication of a consensus definition of Parkinson disease (PD) psychosis in 2007 led to a rapid expansion of literature focusing on clinical aspects, mechanisms and treatment. The authors review this literature and discuss the evolving view of PD psychosis, from distinct classes of symptoms to a continuum progressing over the course of PD.
Abstract | Full Text | PDF

Gene discovery in amyotrophic lateral sclerosis: implications for clinical management
Ammar Al-Chalabi, Leonard H. van den Berg & Jan Veldink
Published online: 16 December 2016
p96 | doi:10.1038/nrneurol.2016.182
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease predominantly affecting upper and lower motor neurons. Here, the authors outline previous and current efforts to characterize genes that are associated with ALS, and describe what is currently known about the genetic architecture of ALS.
Abstract | Full Text | PDF | Supplementary information

Treatment decisions in multiple sclerosis — insights from real-world observational studies
Maria Trojano et al.
Published online: 13 January 2017
p105 | doi:10.1038/nrneurol.2016.188
Real-world observational studies have the potential to answer questions about multiple sclerosis (MS) treatment that randomized controlled trials cannot. Trojano and colleagues discuss the pitfalls and necessary safeguards in observational studies, and the insights that such studies have provided into treatment decisions for patients with MS.
Abstract | Full Text | PDF


Precision medicine for disease modification in Parkinson disease
Alberto J. Espay, Patrik Brundin & Anthony E. Lang
Published online: 20 January 2017
p119 | doi:10.1038/nrneurol.2016.196
In this Perspectives article, Espay and colleagues argue that that the adoption of precision medicine in Parkinson disease will require a revision of biomarker development efforts, with the ultimate goal of testing putative disease-modifying interventions in well-defined disease subgroups.
Full Text | PDF

Erratum: Unruptured intracranial aneurysms: development, rupture and preventive management
Nima Etminan & Gabriel J. Rinkel
Published online: 01 February 2017
p126 | doi:10.1038/nrneurol.2017.14

Full Text | PDF

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events
Nature Reviews Neurology was previously published as Nature Clinical Practice Neurology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group